Italia markets closed

Saniona AB (publ) (0RQJ.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a watchlist
1,8680+0,0280 (+1,52%)
Alla chiusura: 02:20PM BST

Saniona AB (publ)

Smedeland 26B
Glostrup 2600
Denmark
45 70 70 52 25
https://www.saniona.com

Settore/i
Settore
Impiegati a tempo pieno23

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Jorgen Drejer Ph.D.Founder, Chairman & Deputy CEO3,28MN/D1955
Mr. Thomas Feldthus M.Sc., MBACo-Founder & CEO2,32MN/D1960
Ms. Anita Milland B.Com.Chief Financial OfficerN/DN/D1968
Mr. Karin Sandager Nielsen Ph.D.Chief Scientific OfficerN/DN/D1970
Mr. Palle Christophersen M.S., Ph.D.Executive Vice President of Research1,38MN/D1958
Mr. Janus Schreiber LarsenChief Development OfficerN/DN/D1972
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which has completed Phase 1 clinical stage for neuropathic pain conditions; SAN903 for inflammatory and fibrotic disorders; and SAN2219, that is in preclinical stage for treatment of epilepsy. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS; and research collaboration with AstronauTx to identify new treatments for Alzheimer's disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Saniona AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.